Subscribe
scientist-istock-505918900-1
gevende / iStockphoto.com
11 December 2018Biotechnology

AstraZeneca to launch CRISPR-based cancer research centre

Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
CRISPR babies still too risky, warns new report
10 September 2020   Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.
Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Biotechnology
Cancer Research UK forms immunotherapy alliance
28 March 2019   Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.


Editor's picks

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025

Editor's picks

Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025

More on this story

Americas
CRISPR babies still too risky, warns new report
10 September 2020   Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.
Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Biotechnology
Cancer Research UK forms immunotherapy alliance
28 March 2019   Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.

More on this story

Americas
CRISPR babies still too risky, warns new report
10 September 2020   Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.
Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Biotechnology
Cancer Research UK forms immunotherapy alliance
28 March 2019   Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.

More features

Fed Circ: Generic doesn’t infringe Metacel MS drug
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
Strategic IP protection for biotech-related GenAI
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
In vivo cell therapy: A world beyond ex vivo engineering
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley